CSIMarket Company Name, Ticker, Industry, else..
 
Nextcure Inc   (NASDAQ: NXTC)
 
Price: $8.4200 $0.60 7.673%
Day's High: $8.640000343322754 Week Perf: 23.82 %
Day's Low: $ 7.05 30 Day Perf: 44.18 %
Volume (M): 94,743 52 Wk High: $ 15.74
Volume (M$): $ 0 52 Wk Avg: $8.85
Open: $7.47 52 Wk Low: $1.55



 Market Capitalization (Millions $) 45
 Shares Outstanding (Millions) 5
 Employees 40
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -43
 Cash Flow (TTM) (Millions $) 10
 Capital Exp. (TTM) (Millions $) 0

Business Description


NextCure Inc. is a biopharmaceutical company that focuses on developing immunomedicines for the treatment of cancer and other immune-related diseases. The company's approach involves understanding and targeting key immune cell populations to develop novel therapies. They aim to uncover new insights into the complex interactions between immune cells and cancer cells, with the ultimate goal of developing innovative treatments that can benefit patients. NextCure's research and development efforts involve the discovery and development of therapeutic antibodies and other immune modulators. Overall, NextCure Inc. is dedicated to advancing the field of immunotherapy and improving patient outcomes in the battle against cancer and immune-related disorders.


   Company Address: 9000 Virginia Manor Road Beltsville 20705 MD
   Company Phone Number: 399-4900   Stock Exchange / Ticker: NASDAQ NXTC


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
RYTM   -4.08%    
TGTX        2.65% 
VNDA   -1.3%    
VRTX   -2.87%    
ZLAB   -0.2%    
ZYME   -4.42%    
• View Complete Report
   



Clinical Study

NextCures LNCB74 IND Approval Pioneering Hope in B7-H4-Targeted Cancer Therapy,

Published Mon, Dec 30 2024 7:00 AM UTC

Innovative Advancements in Cancer Therapy: NextCure s LNCB74 IND Application Acceptance The landscape of oncology therapeutics is on the brink of transformation with NextCure’s recent announcement. The biotechnology company has received approval from the Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for LNCB74, a groundbreaking antib...
Clinical Study

Innovations in Osteogenesis Imperfecta Treatment Promising Preclinical Findings and Market Dynamics for NextCure Inc

Published Tue, Nov 19 2024 1:05 PM UTC

Osteogenesis imperfecta (OI), characterized by brittle bones and high susceptibility to fractures, has long posed significant challenges in medical management. Recent advancements in therapeutic strategies, particularly involving the treatment of Siglec-15, offer promising new avenues for enhancing bone quality and strength in individuals suffering from moderate-to-severe fo...
Clinical Study

NextCures Strategic Advances and Financial Performance A Comprehensive Overview of Q3 2024

Published Thu, Nov 7 2024 9:05 PM UTC

In an era where the incessant pursuit of medical innovation remains paramount, NextCure, Inc. (Nasdaq: NXTC) has emerged as a prominent player in the biopharmaceutical landscape, particularly within the realm of oncology. On 7 November 2024, the company disseminated a significant business update alongside its financial results for the third quarter of 2024, reflecting both i...
Clinical Study

NextCure Advances Oncological Innovations Promising Preclinical and Clinical Data Unveiled at Leading Medical Confere...

Published Tue, Nov 5 2024 9:05 PM UTC

In a significant stride towards revolutionizing cancer treatment, NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company, presented compelling preclinical and clinical data at recent prestigious meetings, including the Society for Immunotherapy of Cancer (SITC) Annual Meeting and the American Society of Clinical Oncology (ASCO) Annual Meeting. This unveili...
Clinical Study

Beacon of Hope NextCure Reveals Promising NC410 and Pembrolizumab Results for Hard-to-Treat Cancers at ESMO 2024,

Published Mon, Sep 16 2024 12:05 PM UTC

Forging New Frontiers in Cancer Therapy: NextCure Unveils Promising Phase 1b Study Results at ESMO 2024 BELTSVILLE, Md. Sept. 16, 2024 In a stirring presentation, NextCure, Inc. (Nasdaq: NXTC) revealed groundbreaking clinical data at the European Society for Medical Oncology (ESMO) 2024 Congress. This clinical-stage biopharmaceutical company, steadfast in its mission to ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 3.68
PEG (TTM) -

Financial Strength Current
Quick Ratio 3.13
Working Capital Ratio 3.47
Leverage Ratio (MRQ) 0.86
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -11.21 $
Revenues (TTM) -
Cash Flow (TTM) 1.94 $
Cash 3.78 $
Book Value 2.29 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,068,700
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.